HEPA - צמיחת הכנסות ב-12 חודשים נגררים hepionpharma.com

Global supply chain disruptions and patent barriers are creating critical risks for the pharmaceutical sector. The situation for Hepion Pharmaceuticals (HEPA) is exacerbated by the complete halt of all R&D programs and the liquidation of operational activities. The company previously implemented AI to identify liver fibrosis biomarkers. Annual sales growth over the trailing four quarters illustrates this decline, and 0.00 captures the current value of the indicator.
פילוחי נתונים אנליטיים מרוכזים עבור hepionpharma.com (HEPA)

For Hepion Pharmaceuticals (HEPA), which integrates ESG standards into the development of liver disease treatments, analyzing the year-over-year sales growth rate over a rolling four-quarter period allows for an assessment of the effectiveness of innovation commercialization. This metric measures the percentage change in TTM revenue relative to the same period last year, helping investors determine the pace of business scaling relative to the US industry cycle and the risks of capital stagnation.